Nathansen, Jacqueline
Lukiyanchuk, Vasyl
Hein, Linda
Stolte, Maya-Isabel
Borgmann, Kerstin
Löck, Steffen
Kurth, Ina https://orcid.org/0000-0001-9261-5165
Baumann, Michael
Krause, Mechthild
Linge, Annett https://orcid.org/0000-0001-9636-1721
Dubrovska, Anna https://orcid.org/0000-0002-3375-1500
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (401326337, 416001651, BO1868-5)
Wilhelm Sander-Stiftung (2017.106.1)
Bundesministerium für Bildung und Forschung (03Z1NN11, 02NUK032, 02NUK035B)
Article History
Received: 23 December 2020
Revised: 29 April 2021
Accepted: 13 May 2021
First Online: 2 June 2021
Compliance with ethical standards
:
: In the past 5 years, MK received funding for her research projects by IBA (2016), Merck KGaA (2014–2018 for preclinical study; 2018–2020 for clinical study), Medipan GmbH (2014–2018). In the past 5 years, MK, AL, and SL have been involved in an ongoing publicly funded (German Federal Ministry of Education and Research) project with the companies Medipan, Attomol GmbH, GA Generic Assays GmbH, Gesellschaft für medizinische und wissenschaftliche genetische Analysen, Lipotype GmbH and PolyAn GmbH (2019–2021). For the present manuscript, none of the above mentioned funding sources were involved. In the past 5 years, MB received funding for his research projects and for educational grants to the University of Dresden by Bayer AG (2016–2018), Merck KGaA (2014-open) and Medipan GmbH (2014–2018). He is on the supervisory board of HI-STEM gGmbH (Heidelberg) for the German Cancer Research Center (DKFZ, Heidelberg) and also member of the supervisory body of the Charité University Hospital, Berlin. As former chair of OncoRay (Dresden) and present CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg), he has been or is responsible for collaborations with a multitude of companies and institutions, worldwide. In this capacity, he has discussed potential projects and signed contracts for research funding and/or collaborations with industry and academia for his institute(s) and staff, including but not limited to pharmaceutical companies such as Bayer, Boehringer Ingelheim, Bosch, Roche and other companies such as Siemens, IBA, Varian, Elekta, Bruker, etc. In this role, he was/is also responsible for the commercial technology transfer activities of his institute(s), including the creation of start-ups and licensing. This includes the DKFZ-PSMA617 related patent portfolio [WO2015055318 (A1), ANTIGEN (PSMA)] and similar IP portfolios. MB confirms that, to the best of his knowledge, none of the above funding sources were involved in the preparation of this paper. Other co-authors declare no competing financial interests.